文献速递先天性心脏病外科

房室瓣修复对单心室多阶段姑息治疗结果的影响

Effect of Atrioventricular Valve Repair on Multistage Palliation Results of Single-Ventricle Defects.
PubMed 文献 · Ann Thorac Surg · 2020-05-23

该研究回顾了603例2002至2012年接受初始单心室姑息手术的婴儿,其中60例进行了房室瓣修复。竞争风险分析显示,修复后10年18%需再次房室瓣手术,26%死亡或移植,56%存活且无需再手术。首次阶段修复和系统心室功能降低与较差的无移植生存相关。

要点

  • 房室瓣修复在单心室姑息各阶段均可进行,但首次阶段修复预后较差。
  • 修复后10年无移植生存率在首次阶段、Glenn和Fontan阶段分别为38%、65%和100%。
  • 系统心室功能降低是影响无移植生存的因素之一。

核心结论

  • 首次阶段行房室瓣修复和系统心室功能降低与单心室患者较差的无移植生存相关。

研究设计与样本

  • 回顾性队列研究,纳入603例2002至2012年接受初始单心室姑息手术的婴儿,其中60例进行了房室瓣修复。

主要发现

  • 房室瓣修复在首次阶段10例、Glenn阶段27例、Fontan阶段23例进行,修复时中位年龄6.9个月(IQR 4.2-24.1个月)。
  • 修复后房室瓣反流无/微量21例(35%),轻度21例(35%),中度及以上17例(30%)。
  • 竞争风险分析显示,修复后10年18%再次房室瓣手术,26%死亡或移植,56%存活且无需再手术。
  • 无移植生存率在首次阶段、Glenn、Fontan修复分别为38%、65%、100%(P = .0011)。
  • 无移植生存率在三尖瓣、二尖瓣、共同房室瓣修复分别为74%、83%、56%(P = .344)。

临床怎么用

  • 对于首次阶段需行房室瓣修复的高风险患者,可考虑调整初始姑息方式、房室瓣修复时机或列入移植名单。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The presence of significant atrioventricular valve (AVV) regurgitation results in unfavorable conditions that affect the success of single-ventricle (SV) multistage palliation. We report our institution's AVV repair experience. METHODS: We examined incidence of AVV repair in 603 infants who underwent initial SV palliative surgery from 2002 to 2012. We explored patients' characteristics and anatomic and operative details associated with death, transplantation, and AVV reoperation. RESULTS: AVV repair was performed in 60 patients during first-stage (n = 10), Glenn (n = 27), and Fontan (n = 23). Median age at AVV repair was 6.9 months (interquartile range, 4.2-24.1 months). Underlying SV anomaly was hypoplastic left heart syndrome (n = 30), heterotaxy (n = 15), and other (n = 15). The AVV was tricuspid (n = 34), mitral (n = 6), or common (n = 20). Preoperatively, all patients had AVV regurgitation moderate or higher, and 7 (12%) had ventricular dysfunction moderate or higher. After the repair, AVV regurgitation was none/trivial in 21 (35%), mild in 21 (35%), and moderate or higher in 17 (30%). Competing risks analysis showed that 10 years after AVV repair, 18% of patients had undergone AVV reoperation, 26% had died or undergone transplantation, and 56% were alive without subsequent reoperation. Transplant-free survival was 38%, 65%, and 100% for AVV repair at first-stage, Glenn, or Fontan (P = .0011), respectively, and was 74%, 83%, and 56% for tricuspid, mitral, and common AVV repair (P = .344), respectively. Factors associated with transplant-free survival were timing of AVV repair, underlying SV anomaly, and systemic ventricle function. CONCLUSIONS: AVV repair at the first-stage operation and reduced systemic ventricle function are associated with poor outcomes. In those high-risk patients, different approaches that involve initial palliation mode, timing of AVV repair, or listing for transplantation might be warranted.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Sinha R, Altin HF, McCracken C, et al. Effect of Atrioventricular Valve Repair on Multistage Palliation Results of Single-Ventricle Defects. Ann Thorac Surg. 2020. PMID: 32454017. doi:10.1016/j.athoracsur.2020.03.126

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。